Scientists probe eye fluid secrets to personalize glaucoma treatment

NCT ID NCT04412096

Completed Knowledge-focused Sponsor: Ohio State University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how the eye produces and drains fluid to understand why glaucoma medications lower eye pressure more in some people than others. Researchers measured eye fluid production, drainage, and pressure in 59 adults with glaucoma or high eye pressure before and after treatment with timolol or latanoprost eye drops. The goal is to find factors that predict a patient's response to these drugs, moving away from a trial-and-error approach.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Timolol 0.5% eye drops and Latanoprost 0.005% eye drops
What this could lead to: If successful, this could help doctors predict which glaucoma drug will work best for each patient, leading to more personalized and effective treatment.
What could go wrong: This is a small, completed study focused on understanding eye pressure factors, not on proving a new treatment works. The findings may not lead to immediate changes in clinical practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLAUCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

eye disorder glaucoma ocular hypertension open-angle glaucoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLAUCOMA OHT - OCULAR HYPERTENSION

Contacts and locations

Locations

Mayo Clinic

Rochester, Minnesota, 55905, United States
The Ohio State University

Columbus, Ohio, 43212, United States
University of Nebraska Medical Center

Omaha, Nebraska, 68105, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.